Abstract: An entry/exit management system includes: an authentication unit that performs image authentication of a user who passes through a specific area; an attribute acquisition unit that obtains attribute information about a first user when there are the first user who has succeeded in the image authentication and a second user who has failed in the image authentication; a determination unit that determines an allowable number of people who can accompany the first user, on the basis of the attribute information; and a permission unit that permits the second user to pass through the specific area together with the first user, when the number of the second users is less than or equal to the allowable number of people.

Abstract: To provide an information processing apparatus, an information processing method, and a program for restraining a burden on a user who observes a three-dimensional image. Therefore, a display control unit performs display control to cause a three-dimensional image to be displayed so that a first plane surface parallel to a horizontal plane in a real space is observed in an area based on a distance between a lower end and an upper end of a display surface on which a display unit displays the three-dimensional image and an angle between the horizontal plane and the display surface.

Abstract: There is provided a film forming apparatus for performing a film forming process on substrates by heating the substrates while the substrates are held in a shelf shape by a substrate holder in a vertical reaction container. The film forming apparatus includes: an exhaust part configured to evacuate the reaction container; a gas supply part configured to supply a film forming gas into the reaction container; a heat insulating member provided above or below an arrangement region of the substrates to overlap with the arrangement region and configured to thermally insulate the arrangement region from an upper region above the arrangement region or a lower region below the arrangement region; and a through-hole provided in the heat insulating member at a position overlapping with central portions of the substrates to adjust a temperature distribution in a plane of each substrate held near the heat insulating member.

Abstract: There is provided a film forming apparatus for performing a film forming process on substrates by heating the substrates while the substrates are held in a shelf shape by a substrate holder in a vertical reaction container. The film forming apparatus includes: an exhaust part configured to evacuate the reaction container; a gas supply part configured to supply a film forming gas into the reaction container; a heat insulating member provided above or below an arrangement region of the substrates to overlap with the arrangement region and configured to thermally insulate the arrangement region from an upper region above the arrangement region or a lower region below the arrangement region; and a through-hole provided in the heat insulating member at a position overlapping with central portions of the substrates to adjust a temperature distribution in a plane of each substrate held near the heat insulating member.

Abstract: Compounds or pharmacologically acceptable salts thereof for promoting osteogenesis, improving bone metabolism, preventing or treating bone fracture, preventing or treating a disease associated with bone metabolism, or in the field of orthopedics for the promotion of healing of bone fracture, a bone defect, and bone diseases such as osteoarthritis as well as in the field of dentistry for the treatment of periodontal disease and the stabilization of artificial tooth root.

Abstract: Provide a nuclear reactor power monitoring technology for enhancing the monitoring accuracy and reliability in nuclear thermal hydraulic stability.

Abstract: An apparatus for monitoring nuclear thermal hydraulic stability of a nuclear reactor, contains: a calculation unit configured to calculate a stability index of a nuclear thermal hydraulic phenomenon based on nuclear instrumentation signals, the signals being outputted by a plurality of nuclear instrumentation detectors placed at regular intervals in a reactor core; a simulation unit configured to simulate the nuclear thermal hydraulic phenomenon based on a physical model by using information on an operating state of the nuclear reactor as an input condition; a limit value updating unit configured to update a limit value of the nuclear thermal hydraulic phenomenon based on a result of the simulation; and a determination unit configured to determine, based on the stability index and the limit value, whether or not to activate a power oscillation suppressing device.

Abstract: According to one embodiment, a reactor oscillation power range monitor includes: a receiving unit configured to receive LPRM signals issued by LPRM detectors differing in vertical position out of a plurality of LPRM detectors placed in a reactor core; a specification unit configured to specify any exclusion signal which meets an exclusion condition out of the received LPRM signals; an estimation unit configured to estimate an alternative signal for the exclusion signal based on a regular signal which does not meet the exclusion condition out of the received LPRM signals; an arithmetic averaging unit configured to output an arithmetically averaged signal obtained by arithmetically averaging the regular signal and the alternative signal; a time averaging unit configured to output a time-averaged signal obtained by time-averaging the arithmetically averaged signal; and a calculation unit configured to output a standard value obtained by dividing the arithmetically averaged signal by the time-averaged signal.

Abstract: Compounds or pharmacologically acceptable salts thereof for promoting osteogenesis, improving bone metabolism, preventing or treating bone fracture, preventing or treating a disease associated with bone metabolism, or in the field of orthopedics for the promotion of healing of bone fracture, a bone defect, and bone diseases such as osteoarthritis as well as in the field of dentistry for the treatment of periodontal disease and the stabilization of artificial tooth root.

Abstract: Provide a nuclear reactor power monitoring technology for enhancing the monitoring accuracy and reliability in nuclear thermal hydraulic stability.

Abstract: An apparatus for monitoring nuclear thermal hydraulic stability of a nuclear reactor, contains: a calculation unit configured to calculate a stability index of a nuclear thermal hydraulic phenomenon based on nuclear instrumentation signals, the signals being outputted by a plurality of nuclear instrumentation detectors placed at regular intervals in a reactor core; a simulation unit configured to simulate the nuclear thermal hydraulic phenomenon based on a physical model by using information on an operating state of the nuclear reactor as an input condition; a limit value updating unit configured to update a limit value of the nuclear thermal hydraulic phenomenon based on a result of the simulation; and a determination unit configured to determine, based on the stability index and the limit value, whether or not to activate a power oscillation suppressing device.

Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Abstract: The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Abstract: A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Abstract: A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and/or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and/or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column. A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.